Legal & General Group Plc Buys Shares of 1,455,514 BioCryst Pharmaceuticals, Inc. $BCRX

Legal & General Group Plc purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 1,455,514 shares of the biotechnology company’s stock, valued at approximately $14,555,000.

Other large investors also recently modified their holdings of the company. Royal Bank of Canada raised its stake in shares of BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in BioCryst Pharmaceuticals by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock worth $1,019,000 after purchasing an additional 8,517 shares during the period. Goldman Sachs Group Inc. grew its position in BioCryst Pharmaceuticals by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after buying an additional 640,704 shares in the last quarter. Caxton Associates LLP bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at about $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in BioCryst Pharmaceuticals by 11.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock valued at $3,363,000 after buying an additional 47,355 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Royal Bank Of Canada decreased their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Wedbush dropped their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Needham & Company LLC reduced their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Finally, Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $9.82 on Monday. The company has a market capitalization of $2.51 billion, a PE ratio of -6.55 and a beta of 0.56. The stock has a fifty day moving average of $9.71 and a 200-day moving average of $9.07. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15. The business had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The company’s quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.15 EPS. As a group, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.